GlassScriptPhysician profile
Luis D Diaz
NPI 1245677426
$7,482.63
in general payments reported to CMS, 2019-2025
38 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $195 · 2021: $937 · 2022: $1,229 · 2023: $1,359 · 2024: $1,637 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,121.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.47 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,089.69 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $752.00 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $733.01 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $675.06 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.82 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $402.65 | 2022-2025 | Bexsero, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $327.14 | 2021-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $191.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $151.12 | 2021-2025 | Spravato |
| Amgen INC. | $132.35 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $110.62 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.50 | 2022-2025 | |
| Sanofi Pasteur INC. | $77.55 | 2021-2025 | |
| Exact Sciences Corporation | $67.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $61.03 | 2022-2025 | Auvelity |
| Seqirus USA INC | $59.83 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Phathom Pharmaceuticals, INC. | $51.25 | 2025 | Voquezna |
| Renalytix Ai, INC. | $44.73 | 2022 | |
| Neurocrine Biosciences, INC. | $38.70 | 2025 | |
| Merck Sharp & Dohme LLC | $28.44 | 2022-2025 | Rotateq, Vaxelis, Capvaxive |
| Ceribell, INC. | $27.75 | 2025 | Pocket Eeg Device |
| Amarin Pharma, INC. | $24.62 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.14 | 2021 | |
| Allergan, INC. | $21.01 | 2022 | |
| Medtronic, INC. | $19.61 | 2023 | Inpen Smart Insulin Delivery System |
| Agile Therapeutics, INC. | $19.27 | 2022 | |
| Indivior INC. | $18.97 | 2024 | Sublocade |
| Dexcom, INC. | $18.50 | 2022 | |
| Corium, LLC | $18.29 | 2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $17.74 | 2024 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $16.62 | 2023 | Glassia |
| Ibsa Pharma INC. | $16.34 | 2025 | Tirosint, Flector, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $15.63 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.91 | 2022 | |
| Verona Pharma, INC. | $13.88 | 2025 | Ohtuvayre |
| Optinose US, INC. | $13.27 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.